Bausch Health Companies Inc. 8-K

What Happened

• On January 2, 2026, Bausch + Lomb Corporation (a Bausch Health subsidiary) entered into the Fourth Amendment to its Credit and Guaranty Agreement and closed a $2,802,125,000 tranche of Replacement Term Loans. The proceeds refinanced Bausch + Lomb’s outstanding term B loans due 2031 and term B loans due 2028. JPMorgan Chase Bank, N.A. acts as administrative agent and other lenders remain party to the amended Credit Agreement.

Key Details

• Replacement Term Loans amount: $2,802,125,000.
• Maturity: January 15, 2031 (extends certain 2028 loans to 2031).
• Interest margins: 3.75% per annum (term SOFR-based) or 2.75% per annum (alternate base rate).
• Margin reductions vs prior loans: 0.50% lower than the Third Amendment Term Loans and 0.25% lower than the First Incremental Term Loans.
• Amortization: 1.00% per annum; first principal installment due June 30, 2026.
• Filing items: reported under Item 1.01 (material agreement), Item 2.03 (creation of a direct financial obligation) and Item 8.01 (press release). The Fourth Amendment is filed as Exhibit 10.1 and the press release as Exhibit 99.1.

Why It Matters

• For investors, the amendment creates a new $2.802B debt obligation but reduces the interest margin on that debt and extends maturities for certain loans to 2031, which can lower near-term refinancing risk and reduce cash interest costs compared with the prior facilities. The loan has modest amortization starting mid-2026; the full amended Credit Agreement and press release are included as exhibits to the 8‑K for further details.